Advm Stock News

In the last trading session, 1.0 million shares of the Adverum Biotechnologies Inc. (NASDAQ:ADVM) were traded, and its beta was 1.09. Most recently the companys share price was $2.02, and it changed around $0.06 or 3.06% from the last close, which brings the market valuation of the company to $203.21M. ADVM currently trades at a Adverum Biotechnologies Inc. (NASDAQ: ADVM) Could See Prices Soar In The Coming Months Read More »

Northern Trust Corp cut its stake in shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) by 6.1% during the 2nd quarter, Holdings Channel reports. The fund owned 921,899 shares of the biotechnology companys stock after selling 59,470 shares during the period. Northern Trust Corps holdings in Adverum Biotechnologies were worth $3,226,000 as of its most recent SEC []

Walleye Trading LLC purchased a new stake in shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 54,711 shares of the biotechnology companys stock, valued at approximately $191,000. Walleye Trading LLC owned approximately 0.06% of []

Tenaya Therapeutics (NASDAQ:TNYA) and Adverum Biotechnologies (NASDAQ:ADVM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability and valuation. Analyst Ratings This is a breakdown of recent ratings and price targets for Tenaya Therapeutics []

Man Group plc increased its stake in shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) by 161.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 128,991 shares of the biotechnology companys stock after purchasing an additional 79,694 shares during the period. []

Adverum Biotechnologies (NASDAQ:ADVM) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, valuation, analyst recommendations, dividends and institutional ownership. Earnings & Valuation This table compares Adverum Biotechnologies and Tenaya Therapeutics top-line revenue, earnings per []

Zacks Investment Research lowered shares of Adverum Biotechnologies (NASDAQ:ADVM) from a buy rating to a hold rating in a research note released on Monday, Zacks.com reports. According to Zacks, Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable []

Zacks Investment Research upgraded shares of Adverum Biotechnologies (NASDAQ:ADVM) from a hold rating to a buy rating in a report released on Wednesday, Zacks.com reports. Zacks Investment Research currently has $2.50 price objective on the biotechnology companys stock. According to Zacks, Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and []

Are these 10 penny stocks on your watch list this week? The post Best Penny Stocks To Buy This Week?

-- Company maintains focus on advancing ADVM-022 at low doses in patients with wet AMD -- -- Company maintains focus on advancing ADVM-022 at low doses in patients with wet AMD --

The stock price of Adverum Biotechnologies, Inc. (Nasdaq: ADVM) increased by over 10% pre-market today. This is why it happened.

Will upcoming events mean big things for these penny stocks? The post 5 Penny Stocks To Watch This Week With Potential Biotech Catalysts appeared first on Penny Stocks to Buy, Picks, News and Informat

-- Results featured in a presentation today at the Retina Society's 54 th Annual Scientific Meeting -- -- Robust aflibercept protein expression sustained through 2 years --

REDWOOD CITY, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,

REDWOOD CITY, Calif., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, t